Keywords: Bristol-Myers Squibb, Ipilimumab, Melano, USA, FDA

Bristol-Myers Squibb’s BLA for ipilimumab in melanoma delayed by US FDA

Article | 03 November 2010

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) says that the Food and Drug Administration has determined that additional time is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in